These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 11512595)
1. Bone disease in multiple myeloma: new markers, new treatments. Joshua D Intern Med J; 2001 Jul; 31(5):261-3. PubMed ID: 11512595 [No Abstract] [Full Text] [Related]
2. Bisphosphonates may potentiate effects of thalidomide-dexamethasone combination in advanced multiple myeloma. Ural AU; Avcu F Am J Hematol; 2006 May; 81(5):385-6; author reply 386. PubMed ID: 16628715 [No Abstract] [Full Text] [Related]
3. High serum levels of complements C3 and C4 as novel markers for myeloma bone disease. Jiang F; Liu H; Liu Z; Song J; Li L; Ding K; Ren Y; Peng F; Shao Z; Fu R Ann Hematol; 2017 Feb; 96(2):331-333. PubMed ID: 27924370 [No Abstract] [Full Text] [Related]
4. The effect of the combination of bisphosphonates and conventional chemotherapy on bone metabolic markers in multiple myeloma patients. Zhang X; Chang C; Zhao Y; Wu L; Zhang Z; Li X Hematology; 2012 Sep; 17(5):255-60. PubMed ID: 22971530 [TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates in multiple myeloma: current status; future perspectives. Jantunen E; Laakso M Br J Haematol; 1996 Jun; 93(3):501-6. PubMed ID: 8652366 [No Abstract] [Full Text] [Related]
6. Update on the pharmacological prevention of skeletal-related events in cancer patients. Kennedy K; Patel H Orthopedics; 2011 Dec; 34(12):982-5. PubMed ID: 22147215 [TBL] [Abstract][Full Text] [Related]
7. Metastatic bone disease and the role of bisphosphonates. Ellis MJ Br J Hosp Med; 1996 Oct 2-15; 56(7):339-45. PubMed ID: 8899222 [No Abstract] [Full Text] [Related]
8. Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma. Sorscher SM; Lockhart AC J Clin Oncol; 2011 Jul; 29(19):2735-6; author reply 2736-8. PubMed ID: 21646612 [No Abstract] [Full Text] [Related]
9. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610 [TBL] [Abstract][Full Text] [Related]
10. Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis? Søe K; Plesner T; Jakobsen EH; Hansen CT; Jørgensen HB; Delaissé JM J Bone Miner Res; 2013 Aug; 28(8):1738-50. PubMed ID: 23427025 [TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy of multiple bone myeloma. Prognostic features and response criteria (First part) (author's transl)]. Bataille R; Morlock G; Rosenberg F; Sany J; Serre H Sem Hop; 1979 Sep 8-15; 55(27-30):1267-70. PubMed ID: 228397 [TBL] [Abstract][Full Text] [Related]
12. Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer. Søe K; Delaissé JM; Jakobsen EH; Hansen CT; Plesner T Acta Oncol; 2014 Apr; 53(4):547-56. PubMed ID: 24164102 [TBL] [Abstract][Full Text] [Related]
13. The role of bisphosphonates in multiple myeloma. Kyle RA Ann Intern Med; 2000 May; 132(9):734-6. PubMed ID: 10787368 [No Abstract] [Full Text] [Related]
15. FDA approves ZOMETA for treatment of cancer-related bone complications. Expert Rev Anticancer Ther; 2002 Apr; 2(2):137-8. PubMed ID: 12113230 [No Abstract] [Full Text] [Related]
16. [Biphosphonates and multiple myeloma]. Mazières B; Laroche M; Cantagrel A Bull Cancer; 1993; 80(10 Suppl):45-9. PubMed ID: 8081030 [No Abstract] [Full Text] [Related]
17. Third North American Symposium on Skeletal Complications of Malignancy: summary of the scientific sessions. Mohla S; Weilbacher KN; Cher ML; Oyajobi BO; Poznak CV; Clohisy DR Cancer; 2003 Feb; 97(3 Suppl):719-25. PubMed ID: 12548568 [TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid: a framework of emerging anticancer evidence throughout the cancer continuum. Terpos E Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S1-2. PubMed ID: 21353175 [No Abstract] [Full Text] [Related]
19. Bisphosphonates--role in cancer therapies. Mehrotra B J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811 [No Abstract] [Full Text] [Related]
20. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]